Talon Resources Targets Ontario Gold Growth After AIM Move and Eagle Lake Acquisition, CEO Says.Watch here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIofina Regulatory News (IOF)

Share Price Information for Iofina (IOF)

Share Price is delayed by 15 minutes
Get Live Data
52.50    0.00 (0.00%)
Bid:
52.00
Ask:
53.00
Spread: 1.00 (1.923%)
Market Cap: £101.68m
IOF Live PriceLast checked at - London Stock Exchange

Intraday Iofina Share Chart

IOSorb Patent Awarded

2 Aug 2013 08:30

RNS Number : 8247K
Iofina PLC
02 August 2013
 



2 August 2013

 

Iofina plc

("Iofina" or the "Company")

(LSE AIM: IOF)

 

 

IOSorb Patent Awarded

 

Iofina, specialists in the exploration and production of iodine and iodine specialty chemical derivatives, is pleased to report that the Company has been awarded a US patent with regards to its IOsorb™ iodine extraction technology.

The new patent was awarded for Iofina's technology, already in use at IO#1 and IO#2, that provides removal of iodine from brine streams that contain hydrocarbon contaminates and are located at the injection site of the operator. These are key components of Iofina's technology as all the Company's sources of iodine are from hydrocarbon contaminated brine streams which are co-produced waste streams associated with shale oil and gas production based at the producer's injection site.

Conventional methods of extracting iodine are typically intolerant of high temperatures and rendered ineffective by hydrocarbon fouling. The conventional iodine extraction systems also are immobile and not modular or mobile like Iofina's WET® IOsorb™ units. This therefore makes conventional iodine extraction systems ill-suited for deployment which is also included in this patent. The issued patent was originally filed in the United States and has been also filed in Chile and Japan shortly thereafter.

Commenting, Chris Fay, Executive Chairman, said: "The IOsorb™ technology is the only technology known which is oil field proven for large scale commercial production of iodine. This patent is a key component in protecting Iofina's IOsorb™ technology utilised in the emerging shale boom in North America.

"We are delighted we have been issued the patent and will continue to finalise the Company's additional patents and trademarks relating to the Company's IOsorb™ technology to ensure a robust intellectual property (IP) portfolio for the Company."

 

 

For further information, please contact:

 

Dr. Chris Fay, Executive Chairman

Iofina plc

Tel: +44(0)20 3006 3135

www.iofina.com

 

Ben Colegrave/Chris Sim/James Rudd

Investec

Tel: +44(0)20 7597 5970

 

Media Contact:

Dominic Barretto

Yellow Jersey PR Limited

Tel: +44(0) 7768 537 739

 

About Iofina

 

Iofina specializes in the exploration and production of iodine, iodine specialty chemical derivatives, produced water and natural gas. Iofina's business strategy is to identify, develop, build, own and operate iodine extraction plants currently focused in North America based on Iofina's WET® IOsorb™ technology. Iofina has iodine production operations in the United States, specifically in Texas, California, Montana, Oklahoma and Wyoming. The Group has complete vertical integration from the production of iodine in the field to the manufacture of the chemical end products derived from iodine to the consumer and the recycling of iodine using iodinated side-streams from waste chemical processes in Europe, North America and Asia. The Group utilizes its portfolio of patented and patent pending technology, proprietary methods and trademarks throughout all business lines.

 

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCUUUBROOAWRRR
Date   Source Headline
14th Jun 20237:00 amRNSIO#9 Iodine Plant Operating
9th May 20237:00 amRNSNotice of AGM
4th May 20237:00 amRNSInvestor Presentation
28th Apr 20234:45 pmRNSHolding(s) in Company
28th Apr 20237:00 amRNSGrant of Share Options
25th Apr 20237:00 amRNS2022 FULL YEAR RESULTS
12th Apr 20237:00 amRNSProduction Update
20th Feb 20237:00 amRNSDirector/PDMR Shareholding
6th Feb 20237:00 amRNSTrading Update
9th Jan 20237:00 amRNSMarket Update
28th Dec 20222:34 pmRNSHolding(s) in Company
14th Dec 20227:00 amRNSIofina Chemical Awarded ISO Certification
21st Nov 20227:00 amRNSChange of Adviser
28th Oct 20227:00 amRNSFinalised Terms for IO9 & Q3 Production Update
26th Sep 202211:06 amRNSSecond Price Monitoring Extn
26th Sep 202211:00 amRNSPrice Monitoring Extension
26th Sep 20227:00 amRNSInterim Results
8th Jul 20227:00 amRNSAdditional Loan Facilities and H1 Update
5th Jul 20228:54 amRNSHolding(s) in Company
22nd Jun 20222:30 pmRNSResult of AGM
20th Jun 20227:00 amRNSAppointment of Chrystal Capital Partners LLP
27th May 20227:00 amRNSNotice of AGM
26th May 20224:15 pmRNSHolding(s) in Company
26th May 20222:15 pmRNSHolding(s) in Company
24th May 20226:15 pmRNSHolding(s) in Company
20th May 20227:10 amRNSInvestor Presentation
18th May 20227:00 amRNSHolding(s) in Company
9th May 20227:00 amRNSFinal Results
5th May 20227:00 amRNSHolding(s) in Company
28th Apr 20228:38 amRNSHolding(s) in Company
19th Apr 20227:00 amRNSQ1 2022 and IO#9 Update
8th Apr 20221:07 pmRNSHolding(s) in Company
17th Mar 20227:00 amRNSDirector/PDMR Shareholding
16th Mar 20227:00 amRNSHolding(s) in Company
14th Mar 20227:00 amRNSDirector/PDMR Shareholding
11th Mar 20227:00 amRNSDirector/PDMR Shareholding
10th Mar 20227:00 amRNSDirector/PDMR Shareholding
9th Mar 20227:00 amRNSGrant of Share Options
8th Mar 20228:51 amRNSHolding(s) in Company
17th Jan 20229:00 amRNSPrice Monitoring Extension
17th Jan 20227:00 amRNSQ4 2021 Update
10th Jan 20227:00 amRNSHolding(s) in Company
10th Jan 20227:00 amRNSHolding(s) in Company
10th Jan 20227:00 amRNSHolding(s) in Company
29th Dec 20217:00 amRNSBusiness Update
20th Oct 202112:44 pmRNSHolding(s) in Company
15th Oct 20217:00 amRNSQ3 2021 Update
12th Oct 20218:47 amRNSHolding(s) in Company
24th Sep 20217:00 amRNSInterim Results
23rd Sep 20214:40 pmRNSSecond Price Monitoring Extn

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.